Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lidocaine,Tetracaine
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Egis Pharmaceuticals PLC
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Crescita Signs Exclusive 8-Country Licensing Agreement with Egis Pharmaceuticals for Pliaglis®
Details : The formulation contains a eutectic mixture of 7% lidocaine and 7% tetracaine that utilizes phase-changing topical cream Peel technology. In clinical studies, the mean duration of anesthesia has been shown to be in the range of 7 to 9 hours after the app...
Brand Name : Pliaglis
Molecule Type : Small molecule
Upfront Cash : $0.7 million
December 13, 2021
Lead Product(s) : Lidocaine,Tetracaine
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Egis Pharmaceuticals PLC
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Lidocaine,Tetracaine
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : STADA Arzneimittel
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Crescita Therapeutics and STADA Enter 15-Country Exclusive Licensing Agreement for Pliaglis®
Details : Under the terms of the Agreement, STADA will be responsible for commercializing Pliaglis in the Territories utilizing its experienced sales force.
Brand Name : Pliaglis
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 18, 2021
Lead Product(s) : Lidocaine,Tetracaine
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : STADA Arzneimittel
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Lidocaine,Tetracaine
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Croma-Pharma
Deal Size : $1.4 million
Deal Type : Licensing Agreement
Crescita Therapeutics Announces 9-Country Licensing Agreement with Croma Pharma for Pliaglis®
Details : Croma will promote Pliaglis directly to physicians through its sales network consisting of approximately 130 members across the Territories. As part of the agreement, Crescita is eligible to receive a combination of upfront, cumulative sales and other mi...
Brand Name : Pliaglis
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 28, 2021
Lead Product(s) : Lidocaine,Tetracaine
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Croma-Pharma
Deal Size : $1.4 million
Deal Type : Licensing Agreement
Lead Product(s) : Lidocaine,Tetracaine
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Juyou Biotechnology
Deal Size : $2.9 million
Deal Type : Licensing Agreement
Crescita Announces Licensing Agreement for Pliaglis® in China
Details : Under the terms of the agreement, Juyou will look after overall clinical development and regulatory filings for Pliaglis with the National Medical Products Administration (the "NMPA", formerly the China State Food and Drug Administration.
Brand Name : Pliaglis
Molecule Type : Small molecule
Upfront Cash : $0.1 million
November 05, 2020
Lead Product(s) : Lidocaine,Tetracaine
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Juyou Biotechnology
Deal Size : $2.9 million
Deal Type : Licensing Agreement
Lead Product(s) : Lidocaine,Tetracaine
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Taro Pharmaceutical Industries
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Crescita to Receive One-time Cash Payment Following Amendment to Pliaglis® U.S. Licensing Agreement
Details : The Company continues to pursue out-licensing partnerships with focus on approximately 20 countries where Pliaglis has already received regulatory approval.
Brand Name : Pliaglis
Molecule Type : Small molecule
Upfront Cash : $3.9 million
July 28, 2020
Lead Product(s) : Lidocaine,Tetracaine
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Taro Pharmaceutical Industries
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?